TITLE

Recent Advances in Obesity Pharmacotherapy

AUTHOR(S)
Mayer, Marcos A.; Höcht, Christian; Puyó, Ana; Taira, Carlos A.
PUB. DATE
January 2009
SOURCE
Current Clinical Pharmacology;Jan2009, Vol. 4 Issue 1, p53
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve cardiometabolic risk factors, different compounds differ in their mechanism of action and safety profile. However, it is still difficult to achieve and maintain therapeutic objectives along time. The aim of the present article is to summarize the main characteristics of available anti-obesity agents and to explore novel agents that may provide significant clinical benefits in the future.
ACCESSION #
60435368

 

Related Articles

  • Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity. Farina, Maria; Baratta, Roberto; Nigro, Angela; Vinciguerra, Federica; Puglisi, Concetta; Schembri, Roberto; Virgilio, Clara; Vigneri, Riccardo; Frittitta, Lucia // Obesity Surgery;Apr2012, Vol. 22 Issue 4, p565 

    Background: Intragastric balloon (BioEnterics Intragastric Balloon, BIB®) or pharmacotherapy are possible options for the treatment of obese patients when traditional approaches have failed. The aim of our study was to compare in obese patients the effect on weight loss and metabolic changes...

  • Obesity Pharmacotherapy from a Regulatory Perspective: Overview and Key Challenges. Hutchinson, N. I.; Ryder, S. W. // Clinical Pharmacology & Therapeutics;May2007, Vol. 81 Issue 5, p756 

    Obesity is an epidemic with tremendous impact on both patients and health-care systems globally. This paper explores some of the questions related to the clinical development of new pharmacotherapies in the context of an evolving regulatory perspective. These include patient entry criteria,...

  • Choosing the Right Weight Loss Medication for Your Patient Requires Careful Consideration. Still, Christopher // Bariatric Times;Dec2015, Vol. 12 Issue 12, p3 

    The author discusses how to match a patient with the right weight loss medication given his risk, medical history and preferences. He cites the 5 Food and Drug Administration (FDA) approved pharmacotherapy options for treating obesity including phentermine, orlistat and phentermine/topiramate...

  • COMMENTARY. Sharma, Arya M. // Evidence Based Medicine;Apr2008, Vol. 13 Issue 2, p41 

    The article comments on the study by M. J. Franz and colleagues on the effectiveness of diet interventions, with or without exercise, in promoting weight loss more than advice alone. According to the author, the study suggests that weight loss advice alone is without benefit and the effective...

  • Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy. Ravussin, Eric; Smith, Steven R.; Mitchell, Julie A.; Shringarpure, Reshma; Shan, Kevin; Maier, Holly; Koda, Joy E.; Weyer, Christian // Obesity (19307381);Sep2009, Vol. 17 Issue 9, p1736 

    The neurohormonal control of body weight involves a complex interplay between long-term adiposity signals (e.g., leptin), and short-term satiation signals (e.g., amylin). In diet-induced obese (DIO) rodents, amylin/leptin combination treatment led to marked, synergistic, fat-specific weight...

  • ANOREXIGENIC DRUGS IN THE TREATMENT OF OBESITY: PAST, PRESENT AND FUTURE. Ştefania, Todea; Gabriel, Hancu // Acta Medica Marisiensis;2019 Supplement, Vol. 65, p69 

    Background: Obesity is a medical condition in which the subject carries an excess weight; and represents a great problem in modern society. Obesity is related to multiple reasons, including diet, lifestyle, pathological conditions, genetic factors or the use of certain medications. It can...

  • Topiramate: An effective add-on treatment in obese, drug-naïve patients with type 2 diabetes.  // Formulary;Sep2007, Vol. 42 Issue 9, p560 

    The article reports on the result of a study which demonstrated topiramate as an effective add-on treatment to lifestyle changes in obese patients with type 2 diabetes in the U.S. The use of topiramate was also associated with significant reductions in weight, blood pressure and urinary albumin...

  • Challenges in the Discovery and Development of New Agents for the Treatment of Obesity. Staten, M. A. // Clinical Pharmacology & Therapeutics;May2007, Vol. 81 Issue 5, p753 

    New pharmacologic agents are being sought to help manage the epidemic of obesity and its consequences. Understanding the challenges of the history of obesity drugs is wise before investing in new obesity agents. Expectations of patients, physicians, and drug company executives are not consistent...

  • Obesity surgery when combined with an intensive lifestyle intervention program confers a greater advantage over the combination of low energy diet and lifestyle intervention. Papalazarou, A.; Yannakoulia, M.; Komesidou, V.; Dimitriadis, G.; Papakonstantinou, A.; Sidossis, L. // Hellenic Journal of Nutrition & Dietetics;Jan-Jun2011, Vol. 2 Issue 1, p31 

    Aim of the present study was to evaluate the long-term effects of two obesity treatment modalities: lifestyle intervention coupled with surgery and lifestyle intervention coupled with low-energy diet. Material-Methods: A total of 32 morbidly obese women participated in the study. A group of them...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics